Lecanemab: Appropriate Use Recommendations by Korean Dementia Association
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Lecanemab (product name Leqembi®) is an anti-amyloid monoclonal antibody treatment approved for use in Korea for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. The Korean Dementia Association has created recommendations for the appropriate use of lecanemab to assist clinicians. These recommendations include selecting patients for administration, necessary pre-administration tests and preparations, administration methods, monitoring for amyloid related imaging abnormalities (ARIA), and communication with patients and caregivers. Lecanemab is recommended for patients with MCI or mild dementia who confirmed positive amyloid biomarkers, and should not be administered to patients with severe hypersensitivity to lecanemab or those unable to undergo magnetic resonance imaging (MRI) evaluation. To predict the risk of ARIA before administration, apolipoprotein E genotyping is conducted, and regular brain MRI evaluations are recommended to monitor for ARIA during treatment. The most common adverse reactions are infusion-related reactions, which require appropriate management upon occurrence. Additional caution is needed when co-administering with anticoagulants or tissue plasminogen activator due to the risk of macrohemorrhage. Clinicians should consider the efficacy and necessary conditions for administration, as well as the safety of lecanemab, to make a comprehensive decision regarding its use.
Abstract
Lecanemab (product name Leqembi®) is an anti-amyloid monoclonal antibody treatment approved for use in Korea for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. The Korean Dementia Association has created recommendations for the appropriate use of lecanemab to assist clinicians. These recommendations include selecting patients for administration, necessary pre-administration tests and preparations, administration methods, monitoring for amyloid related imaging abnormalities (ARIA), and communication with patients and caregivers. Lecanemab is recommended for patients with MCI or mild dementia who confirmed positive amyloid biomarkers, and should not be administered to patients with severe hypersensitivity to lecanemab or those unable to undergo magnetic resonance imaging (MRI) evaluation. To predict the risk of ARIA before administration, apolipoprotein E genotyping is conducted, and regular brain MRI evaluations are recommended to monitor for ARIA during treatment. The most common adverse reactions are infusion-related reactions, which require appropriate management upon occurrence. Additional caution is needed when co-administering with anticoagulants or tissue plasminogen activator due to the risk of macrohemorrhage. Clinicians should consider the efficacy and necessary conditions for administration, as well as the safety of lecanemab, to make a comprehensive decision regarding its use.
참고문헌 (28)
- van Dyck CH, "Lecanemab in early Alzheimer’s disease", N Engl J Med, 388, pp.9~21 (2023)
- "Prescribing information: leqembi" (2023)[URL]
- "Optimal use promotion guidelines lecanemab (genetical recombination)" (2023)[URL]
- (2024)[URL]
- Cummings J, "Lecanemab : appropriate use recommendations", J Prev Alzheimers Dis, 10, pp.362~377 (2023)
- Swanson CJ, "A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody", Alzheimers Res Ther, 13, pp.80~ (2021)
- Masaki Nakagawa KT, "Clarity AD: analysis in Asian population of a phase III trial of lecanemabin early Alzheimer's disease", The 42nd Annual Meeting of Japan Society for Dementia Research (2023)
- Albert MS, "The diagnosis of mild cognitive impairment due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.270~279 (2011)
- McKhann GM, "The diagnosis of dementia due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.263~269 (2011)
- Reish NJ, "Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke", N Engl J Med, 388, pp.478~479 (2023)
- Auriel E, "Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation", JAMA Neurol, 73, pp.197~202 (2016)
- Salvarani C, "Imaging findings of cerebral amyloid angiopathy, Aβ-related angiitis (ABRA), and cerebral amyloid angiopathy-related inflammation: a single-institution 25-year experience", Medicine (Baltimore), 95, pp.e3613~ (2016)
- Belloy ME, "A quarter century of APOE and Alzheimer’s disease : progress to date and the path forward", Neuron, 101, pp.820~838 (2019)
- Hampel H, "Blood-based biomarkers for Alzheimer disease : mapping the road to the clinic", Nat Rev Neurol, 14, pp.639~652 (2018)
- "Common terminology criteria for adverse events (CTCAE) v5.0" (2017)[URL]
- Barroso A, "Management of infusion-related reactions in cancer therapy : strategies and challenges", ESMO Open, 9, pp.102922~ (2024)
- Lenz HJ, "Management and preparedness for infusion and hypersensitivity reactions", Oncologist, 12, pp.601~609 (2007)
- Sperling RA, "Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials : recommendations from the Alzheimer’s Association research roundtable workgroup", Alzheimers Dement, 7, pp.367~385 (2011)
- Barakos J, "Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with anti-amyloid beta therapy", J Prev Alzheimers Dis, 9, pp.211~220 (2022)
- Cogswell PM, "Amyloid-related imaging abnormalities with emerging alzheimer disease therapeutics : detection and reporting recommendations for clinical practice", AJNR Am J Neuroradiol, 43, pp.E19~E35 (2022)
- Barakos J, "MR imaging features of amyloid-related imaging abnormalities", AJNR Am J Neuroradiol, 34, pp.1958~1965 (2013)
- Greenberg SM, "Cerebral amyloid angiopathy and Alzheimer disease-one peptide, two pathways", Nat Rev Neurol, 16, pp.30~42 (2020)
- Hampel H, "Amyloid-related imaging abnormalities(ARIA) : radiological, biological and clinical characteristics", Brain, 146, pp.4414~4424 (2023)
- Piazza F, "Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation : implications for amyloid-modifying therapies", Ann Neurol, 73, pp.449~458 (2013)
- Filippi M, "Amyloid-related imaging abnormalities and β-amyloid-targeting antibodies : a systematic review", JAMA Neurol, 79, pp.291~304 (2022)
- Jeong SY, "Amyloid-related imaging abnormalities in the era of anti-amyloid beta monoclonal antibodies for Alzheimer’s disease : recent updates on clinical and imaging features and MRI monitoring", Korean J Radiol, 25, pp.726~741 (2024)
- Agarwal A, "Amyloid-related imaging abnormalities in Alzheimer disease treated with anti-amyloid-β therapy", Radiographics, 43, pp.e230009~ (2023)
- Charidimou A, "Emerging concepts in sporadic cerebral amyloid angiopathy", Brain, 140, pp.1829~1850 (2017)